Singulex, Inc.’s Assay For Cardiovascular Risk Assessment Highlighted In Two Presentations At American Heart Association 2013 Scientific Sessions
11/19/2013 7:20:32 AM
Singulex, Inc., the developer and leading provider of Single Molecule Counting (SMC™) technology for clinical diagnostics and scientific discovery, today announced new data highlighting the Company’s ultrasensitive Erenna® Immunoassay System in the detection of cardiac troponin-I (cTnI). Two studies utilized the Erenna System to measure previously undetectable levels of cTnI in order to assess cardiovascular disease risk in rheumatoid arthritis (RA) and heart failure (HF) patients.
Help employers find you! Check out all the jobs and post your resume.
comments powered by